Drug Profile


Alternative Names: MCA C23; TI 23

Latest Information Update: 19 Oct 2000

Price : $50

At a glance

  • Originator Teijin Pharma
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cytomegalovirus infections

Most Recent Events

  • 19 Oct 2000 Discontinued-preregistration for Cytomegalovirus infections in Japan (IV)
  • 11 Oct 1999 Orphan Drug Designation for regavirumab has been withdrawan in Japan
  • 11 May 1999 Investigation in Cytomegalovirus infections in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top